All individual trials at Kinevant Sciences GmbH

3 out of 3

100.0%

Status	Sponsor	Trial ID	Title	Completion date
reported	Kinevant Sciences GmbH	NCT04351243	A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)	2020-12-01
reported	Kinevant Sciences GmbH	NCT05351554	A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis	2022-11-15
reported	Kinevant Sciences GmbH	NCT05314517	A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis	2024-10-16

Download this data